n | Median survival, days (95% CI) | Pb | |
---|---|---|---|
Age, years | |||
< 70 | 232 | 29 (13–52) | 0.003 |
≥ 70 | 255 | 24 (14–40) | |
Sex | |||
Female | 219 | 29 (13–48) | 0.035 |
Male | 268 | 24 (14–40) | |
Cancer site | |||
Gastrointestinal tract | 127 | 29 (14–47) | 0.012 |
Hepatobiliary/pancreatic | 118 | 24 (13–33) | |
Lung | 108 | 22 (12–41) | |
Urogenital tract | 57 | 27 (13–55) | |
Others | 77 | 35 (19–47) | |
ECOG-PS | |||
≤ 2 | 115 | 30 (18–50) | 0.012 |
3 | 189 | 27 (14–48) | |
4 | 183 | 23 (11–40) | |
Active infection | |||
No | 322 | 27 (12–46) | 0.558 |
Yes | 164 | 25 (14–38) | |
Leukocytosis | |||
No | 279 | 31 (15–52) | < 0.001 |
Yes | 208 | 22 (11–34) | |
Neutrophilia | |||
No | 173 | 31 (18–55) | < 0.001 |
Yes | 314 | 24 (12–39) | |
Lymphopenia | |||
No | 90 | 36 (19–60) | < 0.001 |
Yes | 397 | 25 (13–41) | |
Anemia | |||
No | 56 | 25 (13–45) | 0.707 |
Yes | 431 | 26 (14–45) | |
Thrombocytopenia | |||
No | 371 | 28 (14–47) | 0.020 |
Yes | 116 | 20 (11–36) | |
Azotemia | |||
No | 367 | 28 (14–46) | 0.011 |
Yes | 120 | 20 (12–38) | |
Hypoalbuminemia | |||
No | 176 | 35 (20–60) | < 0.001 |
Yes | 311 | 20 (11–37) | |
Hyperbilirubinemia | |||
No | 341 | 29 (15–48) | < 0.001 |
Yes | 145 | 19 (10–32) | |
PT/INR prolongation | |||
No | 259 | 29 (16–51) | < 0.001 |
Yes | 200 | 20 (10–34) | |
C-reactive proteina | |||
Low | 239 | 29 (14–52) | 0.007 |
High | 233 | 22 (12–38) | |
Sodium level | |||
Within normal range | 219 | 28 (14–49) | < 0.001 |
Hyponatremia | 253 | 25 (13–43) | |
Hypernatremia | 15 | 6 (3–28) | |
Potassium level | |||
Within normal range | 394 | 27 (14–46) | 0.118 |
Hypokalemia | 65 | 26 (13–43) | |
Hyperkalemia | 28 | 19 (10–27) |